Details of Disease

General Information of Disease (ID: DISWWLTC)

Disease Name Gastric adenocarcinoma
Synonyms STAD; adenocarcinoma of stomach; gastric adenocarcinoma; adenocarcinoma - stomach; gastric (stomach) adenocarcinoma; adenocarcinoma of the stomach; stomach adenocarcinoma
Disease Class 2B72: Stomach cancer
Definition A carcinoma that arises from glandular epithelial cells of the stomach
Disease Hierarchy
DIS3IHTY: Adenocarcinoma
DISKIJSX: Stomach cancer
DISWWLTC: Gastric adenocarcinoma
ICD Code
ICD-11
ICD-11: 2B72
ICD-9
ICD-9: 151
Expand ICD-9
151
Disease Identifiers
MONDO ID
MONDO_0005036
UMLS CUI
C0278701
MedGen ID
82961
HPO ID
HP:0033770
Orphanet ID
464463
SNOMED CT ID
408647009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 11 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Antacids DM3IAOE Approved NA [1]
Atezolizumab DMMF8U0 Approved Monoclonal antibody [2]
Bavencio DMU9C8F Approved Monoclonal antibody [2]
Carbamazepine DMZOLBI Approved Small molecular drug [3]
Margetuximab DMKEY6S Approved Antibody [2]
Merimepodib DM0HS92 Approved Small molecular drug [4]
Nivolumab DMAB9QE Approved Monoclonal antibody [2]
Ramucirumab DMWUFQ4 Approved Monoclonal antibody [5]
Taxol DMUOT9V Approved Small molecular drug [6]
Trastuzumab DMZQOUX Approved Antibody [2]
Tucatinib DMBESUA Approved NA [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Drug(s)
This Disease is Treated as An Indication in 52 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABP 980 DMEH3LA Phase 3 NA [8]
Andecaliximab DMLDB1X Phase 3 NA [9]
BMS-986205 DM3MAYQ Phase 3 NA [2]
Claudiximab DMPQR1D Phase 3 Antibody [2]
DE-766 DM0GUV2 Phase 3 NA [10]
Edotecarin DM3ZL7D Phase 3 Small molecular drug [11]
G17DT DMMNP2F Phase 3 Antibody [12]
GDC-0068 DMWBZJD Phase 3 Small molecular drug [6]
GRANITE DMV72N6 Phase 3 Small molecular drug [13]
GS-5745 DMP8MDW Phase 3 NA [6]
ICI 118,551 DM3OU54 Phase 3 Small molecular drug [6]
Lonsurf DM9JGQA Phase 3 NA [2]
Nelipepimut S DMDBY30 Phase 3 Small molecular drug [14]
Oraxol DMNDH3J Phase 3 NA [2]
OS-440 DM27Z1L Phase 3 NA [15]
RG3638 DMTQJE0 Phase 3 NA [16]
Rivoceranib DM13V0P Phase 3 Small molecular drug [2]
S-1 DMBVM01 Phase 3 Small molecular drug [17]
Tesetaxel DM9LFYN Phase 3 Small molecular drug [18]
Zolbetuximab DM5ST9Z Phase 3 Antibody [19]
Anti-LAG3 DMJO402 Phase 2 NA [8]
APR-246 DMNFADH Phase 2 Small molecular drug [20]
BAY-57-9352 DMVA5NS Phase 2 Small molecular drug [6]
Bemarituzumab DMWNYIE Phase 2 NA [21]
CRS-207 DMXU5LZ Phase 2 Vaccine [14]
DS-8201 DMYCAN7 Phase 2 NA [8]
GSK1292263 DMDMXKQ Phase 2 Small molecular drug [22]
Matuzumab DM2458E Phase 2 Antibody [23]
MM-111 DMO7MBS Phase 2 Monoclonal antibody [24]
PEGPH20 DM26YJ1 Phase 2 NA [2]
Plevitrexed DM7Y60I Phase 2 Small molecular drug [25]
Plevitrexed (R)-isomer DMTL39C Phase 2 Small molecular drug [26]
XL880 DMHJTR2 Phase 2 Small molecular drug [27]
Anti-HER2 CAR-T DMQD6B9 Phase 1/2 CAR T Cell Therapy [28]
Anti-Mesothelin CAR-T cells DM4NMBW Phase 1/2 CAR T Cell Therapy [29]
Anti-MUC1 CAR-T cells DMTQIB2 Phase 1/2 CAR T Cell Therapy [30]
BPX-601 DMV9QGW Phase 1/2 CAR T Cell Therapy [31]
CAR-T Cells targeting EpCAM DMREQCF Phase 1/2 CAR T Cell Therapy [32]
PAT-SC1 DMZKFJO Phase 1/2 Antibody [33]
A168 DMJW3F4 Phase 1 Monoclonal antibody [34]
AbGn-107 DMRZMPB Phase 1 NA [2]
Alofanib DMIEKTF Phase 1 Small molecular drug [35]
AMG 199 DMWG2K6 Phase 1 Antibody [36]
AMG 910 DMCG7XL Phase 1 Antibody [37]
Anti-CEA CAR-T cells DMA7L3O Phase 1 CAR T Cell Therapy [38]
Anti-CEA-CAR T DMJA3H1 Phase 1 CAR T Cell Therapy [39]
EGFR806-specific CAR T cell DM3AD65 Phase 1 CAR T Cell Therapy [40]
FPA144 DM1EBRK Phase 1 NA [8]
HER2-specific CAR T cell DMJKBWO Phase 1 CAR T Cell Therapy [41]
Minnelide 001 DM5VEN9 Phase 1 NA [6]
XR-5944 DMO9KZE Phase 1 Small molecular drug [42]
EPCAM-targeted CAR-T cells DMV6RMB Clinical trial CAR T Cell Therapy [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 52 Drug(s)
This Disease is Treated as An Indication in 2 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 DMLZMIG Patented Small molecular drug [44]
PMID28460551-Compound-1 DMHV75N Patented Small molecular drug [45]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BBR-3438 DMR569L Discontinued in Phase 2 Small molecular drug [46]
MDL 101,731 DMKEYSX Discontinued in Phase 2 Small molecular drug [47]
TOPIXANTRONE HYDROCHLORIDE DMZA06U Discontinued in Phase 2 Small molecular drug [48]
IPI-493 DMCF0XK Discontinued in Phase 1 Small molecular drug [49]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Kanjinti DM3YJNL Application submitted NA [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anti-CD9 mab DMAU147 Investigative Monoclonal antibody [50]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 44 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CEACAM5 TTY6DTE Limited Biomarker [51]
CTNNB1 TTRPKQG Limited Biomarker [52]
FBXW7 TT29KY7 Limited Biomarker [53]
LATS2 TTML7FG Limited Altered Expression [54]
GAST TT4LRVO moderate Biomarker [55]
KIT TTX41N9 moderate Biomarker [56]
KLF4 TTTI53X moderate Biomarker [57]
MSLN TT4RXME moderate Biomarker [58]
PLCG1 TT6T4JI moderate Biomarker [59]
PSCA TT9T4AV moderate Genetic Variation [60]
ROS1 TTSZ6Y3 moderate Biomarker [61]
S100A8 TT4AF6N moderate Altered Expression [62]
SLC6A5 TTI0138 moderate Biomarker [63]
TOP2A TTCGY2K moderate Genetic Variation [64]
ACVR1 TTJNBQA Strong Genetic Variation [65]
AFP TTCFEA1 Strong Biomarker [51]
B2M TTY7FKA Strong Genetic Variation [65]
BTLA TTER58P Strong Altered Expression [66]
CD276 TT6CQUM Strong Altered Expression [67]
CLDN6 TTKSV48 Strong Biomarker [68]
CLIC1 TT8KZG6 Strong Altered Expression [69]
CREBBP TTFRCTK Strong Genetic Variation [65]
EPHA2 TTRJB2G Strong Altered Expression [70]
ERBB2 TTR5TV4 Strong Altered Expression [71]
ERBB3 TTSINU2 Strong Altered Expression [72]
GPR39 TTTPCNU Strong Biomarker [73]
HDAC8 TTT6LFV Strong Biomarker [74]
HNRNPA2B1 TT8UPW6 Strong Altered Expression [75]
IGFBP6 TTLAYV8 Strong Altered Expression [76]
KRT17 TTKV0EC Strong Biomarker [77]
MAP2K1 TTIDAPM Strong Genetic Variation [65]
MAP2K2 TT8H9GB Strong Genetic Variation [65]
MAPK14 TTQBR95 Strong Biomarker [78]
MLH1 TTISG27 Strong Posttranslational Modification [79]
NRAS TTW2R9X Strong Genetic Variation [65]
PLAC1 TTM18HX Strong Altered Expression [80]
PRKCI TTWJTHX Strong Altered Expression [81]
RHOA TTP2U16 Strong Genetic Variation [65]
SGCB TTEDCQ0 Strong Altered Expression [82]
SLCO2A1 TTKVTQO Strong Biomarker [83]
SSTR3 TTJX3UE Strong Altered Expression [84]
STOML2 TTOI329 Strong Altered Expression [85]
TNS4 TT1K65C Strong Altered Expression [86]
USP33 TT4E85Q Strong Altered Expression [87]
------------------------------------------------------------------------------------
⏷ Show the Full List of 44 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC39A1 DTLWPXS Strong Altered Expression [88]
------------------------------------------------------------------------------------
This Disease Is Related to 86 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACOT1 OTXFL7WM Limited Altered Expression [89]
ISL1 OTVNVKAX Limited Biomarker [90]
LRBA OTOUZN9G Limited Genetic Variation [91]
RIN1 OTPBROUD Limited Biomarker [92]
ING4 OT0VVG4V moderate Biomarker [93]
JRK OTO8E77P moderate Genetic Variation [94]
MAP2K4 OTZPZX11 moderate Biomarker [95]
MYEOV OTDC7UHL moderate Biomarker [63]
PLCE1 OTJISZOX moderate Altered Expression [96]
PRPF38B OTQLH551 moderate Biomarker [63]
TSPAN1 OTZQPIYK moderate Biomarker [63]
A4GALT OTPX3UGY Strong Biomarker [97]
A4GNT OT8GOL3T Strong Biomarker [97]
ANXA7 OTLMD0TK Strong Biomarker [98]
CCDC168 OTB4NE2L Strong Genetic Variation [99]
CCNG2 OTII38K2 Strong Biomarker [82]
CDH17 OT9EV2XK Strong Biomarker [100]
CDX2 OTCG4TSY Strong Altered Expression [101]
CFC1 OT5DHGI8 Strong Biomarker [102]
CLDN3 OT71MN9S Strong Posttranslational Modification [103]
CNMD OTHND8EL Strong Biomarker [104]
CNOT9 OT1NIIQD Strong Genetic Variation [65]
COL5A2 OT5VOSQE Strong Biomarker [105]
COLQ OT4BHUGQ Strong Biomarker [106]
CTNNBIP1 OTX9SBJG Strong Biomarker [107]
CYLD OT37FKH0 Strong Posttranslational Modification [108]
DACT2 OTNLCC0K Strong Altered Expression [109]
DOK2 OTIJ38UF Strong Biomarker [110]
EBAG9 OTTQLQCP Strong Altered Expression [111]
EMC6 OT9IHH51 Strong Altered Expression [112]
EPN3 OTNNYDT6 Strong Altered Expression [113]
ESPL1 OTMGEVOK Strong Altered Expression [114]
FAT4 OT7QONNV Strong Posttranslational Modification [115]
GAB1 OTQKE6V4 Strong Biomarker [116]
GALNT18 OTKIIELC Strong Biomarker [117]
GALNT2 OTZZ5386 Strong Biomarker [118]
GALNTL5 OT93QQKE Strong Biomarker [117]
GCFC2 OTC7FRXL Strong Biomarker [119]
GNAS OTMH8BKJ Strong Genetic Variation [65]
GNL3 OTILGYO4 Strong Altered Expression [57]
GPR15 OTK8674M Strong Biomarker [120]
IFNA17 OTHXRYG3 Strong Genetic Variation [121]
IST1 OTSFEZ2O Strong Biomarker [122]
KLF5 OT1ABI9N Strong Biomarker [123]
KPNA2 OTU7FOE6 Strong Altered Expression [124]
LAYN OT9A9Q1X Strong Biomarker [125]
LETM1 OT8N4MRU Strong Biomarker [126]
LIMS1 OT729S0T Strong Biomarker [127]
MAP6 OTPUI00F Strong Biomarker [128]
MATN3 OTH9H74J Strong Altered Expression [129]
MCC OTQVI1EM Strong Biomarker [130]
MCM5 OTAHLB62 Strong Altered Expression [114]
MED12 OTQZ4D2X Strong Genetic Variation [65]
MGAT5 OTU4DD4G Strong Altered Expression [131]
MUC3A OTI4XUDY Strong Biomarker [58]
MUC6 OTPVL723 Strong Biomarker [132]
NET1 OTZHNMJV Strong Biomarker [133]
NUP35 OT6XNLQC Strong Biomarker [134]
POLE OTFM3MMU Strong Genetic Variation [65]
PPIL3 OT0GPU73 Strong Biomarker [135]
PPP1R1B OTSIJMQ9 Strong Altered Expression [136]
PPP2R1A OTYA3GB4 Strong Genetic Variation [65]
PTPN3 OTSLZBVY Strong Biomarker [137]
PTPN4 OT6SXU5Y Strong Altered Expression [138]
PTPRD OTZPJ3GX Strong Biomarker [139]
PTPRF OTH5KF2D Strong Altered Expression [140]
RAB1A OTKPHRD0 Strong Biomarker [141]
REM1 OTUXL0HC Strong Altered Expression [142]
RIOX2 OT2YFPI2 Strong Biomarker [143]
RTKN OTSS8XR6 Strong Biomarker [144]
RUBCNL OTMQIDOI Strong Biomarker [145]
SBK1 OTCO4NEI Strong Altered Expression [146]
SMAD4 OTWQWCKG Strong Biomarker [147]
SNX10 OT05B7BT Strong Biomarker [148]
SRI OT4R3EAC Strong Genetic Variation [149]
SRSF7 OTRS4W4S Strong Altered Expression [150]
STOM OTC8R6EH Strong Altered Expression [85]
TRAF4 OTJLRVMC Strong Biomarker [151]
TRIM15 OTNYAKP6 Strong Altered Expression [152]
TRIM25 OT35SG1R Strong Biomarker [153]
ALPG OTCIM29R Definitive Altered Expression [154]
ANKRD33 OTPY8R95 Definitive Biomarker [155]
NCOA1 OTLIUJQD Definitive Altered Expression [156]
PALB2 OT6DNDBG Definitive Biomarker [157]
PLAGL1 OTZAO900 Definitive Genetic Variation [158]
SDHA OTOJ8QFF Definitive Biomarker [157]
------------------------------------------------------------------------------------
⏷ Show the Full List of 86 DOT(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7390).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT04499924) Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02). U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT02545504) Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1). U.S. National Institutes of Health.
10 Clinical pipeline report, company report or official report of Daiichi Sankyo.
11 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
12 ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health.
13 ClinicalTrials.gov (NCT00879333) Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). U.S. National Institutes of Health.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031678)
16 ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
17 Clinical pipeline report, company report or official report of Taiho Pharma U.S.A.
18 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
19 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
24 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278).
26 Clinical pipeline report, company report or official report of plevitrexed.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
28 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
29 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
30 ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
31 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
32 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
34 Clinical pipeline report, company report or official report of Klus Pharma
35 ClinicalTrials.gov (NCT04071184) Study of Alofanib in Patients With Metastatic Gastric Cancer. U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT04117958) Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT04260191) Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
39 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
40 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
41 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
42 Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.
43 ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
44 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
45 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007244)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002544)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015071)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026781)
50 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
51 Gastric Hepatoid Adenocarcinoma: Differentiation From Gastric Adenocarcinoma With Dynamic Contrast-Enhanced Computed Tomographic Findings.J Comput Assist Tomogr. 2019 Nov/Dec;43(6):887-891. doi: 10.1097/RCT.0000000000000924.
52 Low expression of PTEN is essential for maintenance of a malignant state in human gastric adenocarcinoma via upregulation of pAURKA mediated by activation of AURKA.Int J Mol Med. 2018 Jun;41(6):3629-3641. doi: 10.3892/ijmm.2018.3544. Epub 2018 Mar 7.
53 FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma.BMC Gastroenterol. 2017 May 2;17(1):60. doi: 10.1186/s12876-017-0616-7.
54 Building of neomycin-nucleobase-amino acid conjugates for the inhibition of oncogenic miRNAs biogenesis.Org Biomol Chem. 2018 Aug 29;16(34):6262-6274. doi: 10.1039/c8ob01858h.
55 Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.Oncotarget. 2016 Jul 19;7(29):45462-45478. doi: 10.18632/oncotarget.9990.
56 KIT performed as a driver gene candidate affecting the survival status of patients with stomach adenocarcinoma.Oncotarget. 2017 Jul 26;8(41):70183-70191. doi: 10.18632/oncotarget.19598. eCollection 2017 Sep 19.
57 Concomitant upregulation of nucleostemin and downregulation of Sox2 and Klf4 in gastric adenocarcinoma.Tumour Biol. 2014 Jul;35(7):7177-85. doi: 10.1007/s13277-014-1966-1. Epub 2014 Apr 25.
58 MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma.J Cell Biochem. 2019 Apr;120(4):5010-5017. doi: 10.1002/jcb.27776. Epub 2018 Sep 27.
59 Lentivirus-mediated PLC1 gene short-hairpin RNA suppresses tumor growth and metastasis of human gastric adenocarcinoma.Oncotarget. 2016 Feb 16;7(7):8043-54. doi: 10.18632/oncotarget.6976.
60 The Influence of PSCA Gene Variation on Its Expression and Gastric Adenocarcinoma Susceptibility in the Northwest Chinese Population.Int J Mol Sci. 2015 May 21;16(5):11648-58. doi: 10.3390/ijms160511648.
61 Identification of ROS1 rearrangement in gastric adenocarcinoma.Cancer. 2013 May 1;119(9):1627-35. doi: 10.1002/cncr.27967. Epub 2013 Feb 7.
62 Helicobacter pylori CagA and gastric carcinogenesis.Asian Pac J Cancer Prev. 2012;13(12):6305-10. doi: 10.7314/apjcp.2012.13.12.6305.
63 Net1 and Myeov: computationally identified mediators of gastric cancer.Br J Cancer. 2006 Apr 24;94(8):1204-12. doi: 10.1038/sj.bjc.6603054.
64 Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.BMC Cancer. 2008 Dec 6;8:363. doi: 10.1186/1471-2407-8-363.
65 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
66 Ectopic expression of B and T lymphocyte attenuator in gastric cancer: a potential independent prognostic factor in patients with gastric cancer.Mol Med Rep. 2015 Jan;11(1):658-64. doi: 10.3892/mmr.2014.2699. Epub 2014 Oct 20.
67 Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.Medicine (Baltimore). 2019 Feb;98(8):e14663. doi: 10.1097/MD.0000000000014663.
68 Claudin-6 enhances cell invasiveness through claudin-1 in AGS human adenocarcinoma gastric cancer cells.Exp Cell Res. 2017 Jan 1;350(1):226-235. doi: 10.1016/j.yexcr.2016.11.025. Epub 2016 Dec 1.
69 PA28 regulates cell invasion of gastric cancer via modulating the expression of chloride intracellular channel 1.J Cell Biochem. 2012 May;113(5):1537-46. doi: 10.1002/jcb.24022.
70 Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner.J Cancer Res Clin Oncol. 2018 Sep;144(9):1649-1663. doi: 10.1007/s00432-018-2683-8. Epub 2018 Jun 12.
71 The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.Oncologist. 2019 Sep;24(9):e854-e863. doi: 10.1634/theoncologist.2018-0741. Epub 2019 Mar 7.
72 Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.PLoS One. 2016 Feb 4;11(2):e0148101. doi: 10.1371/journal.pone.0148101. eCollection 2016.
73 The role of the obestatin/GPR39 system in human gastric adenocarcinomas.Oncotarget. 2016 Feb 2;7(5):5957-71. doi: 10.18632/oncotarget.6718.
74 The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.Int J Oncol. 2015 Nov;47(5):1819-28. doi: 10.3892/ijo.2015.3182. Epub 2015 Sep 24.
75 Aberrant expression and localization of hnRNP-A2/B1 is a common event in human gastric adenocarcinoma.J Gastroenterol Hepatol. 2011 Jan;26(1):108-15. doi: 10.1111/j.1440-1746.2010.06482.x.
76 Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis.Oncol Lett. 2017 Jun;13(6):4161-4168. doi: 10.3892/ol.2017.5993. Epub 2017 Apr 5.
77 Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells. Gastric Cancer. 2017 Nov;20(6):948-959.
78 PlGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways.Cell Biochem Funct. 2016 Apr;34(3):173-80. doi: 10.1002/cbf.3176. Epub 2016 Mar 9.
79 Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa.Pathol Int. 2001 Apr;51(4):240-7. doi: 10.1046/j.1440-1827.2001.01197.x.
80 Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.Oncol Rep. 2018 Jan;39(1):53-60. doi: 10.3892/or.2017.6086. Epub 2017 Nov 9.
81 Expression of Stathmin1 in gastric adenocarcinoma.Anticancer Res. 2014 Aug;34(8):4217-21.
82 Effect of cyclin G2 on proliferative ability of SGC-7901 cell.World J Gastroenterol. 2004 May 1;10(9):1357-60. doi: 10.3748/wjg.v10.i9.1357.
83 Reduction of prostaglandin transporter predicts poor prognosis associated with angiogenesis in gastric adenocarcinoma.J Gastroenterol Hepatol. 2016 Feb;31(2):376-83. doi: 10.1111/jgh.13079.
84 The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells.Cancer Biol Ther. 2004 Aug;3(8):726-30. doi: 10.4161/cbt.3.8.962. Epub 2004 Aug 10.
85 Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study.Med Oncol. 2014 Jan;31(1):763. doi: 10.1007/s12032-013-0763-9. Epub 2013 Nov 21.
86 Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.Oncotarget. 2017 Sep 20;8(48):84112-84122. doi: 10.18632/oncotarget.21109. eCollection 2017 Oct 13.
87 Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma.Med Sci Monit. 2018 May 26;24:3496-3505. doi: 10.12659/MSM.908075.
88 Persistent low expression of hZip1 in mucinous carcinomas of the ovary, colon, stomach and lung.J Ovarian Res. 2015 Jun 17;8:40. doi: 10.1186/s13048-015-0169-8.
89 ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma.Hum Pathol. 2018 Jul;77:35-44. doi: 10.1016/j.humpath.2018.03.013. Epub 2018 Mar 17.
90 An abnormally high expression of ISL-1 represents a potential prognostic factor in gastric cancer.Hum Pathol. 2015 Sep;46(9):1282-9. doi: 10.1016/j.humpath.2015.05.006. Epub 2015 May 27.
91 Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.Orphanet J Rare Dis. 2017 Jul 18;12(1):131. doi: 10.1186/s13023-017-0682-5.
92 High RIN1 expression is associated with poor prognosis in patients with gastric adenocarcinoma.Tumour Biol. 2012 Oct;33(5):1557-63. doi: 10.1007/s13277-012-0409-0. Epub 2012 May 6.
93 Down-regulation of ING4 is associated with initiation and progression of lung cancer.Histopathology. 2010 Aug;57(2):271-81. doi: 10.1111/j.1365-2559.2010.03623.x.
94 Loss-of-function variants in ATM confer risk of gastric cancer.Nat Genet. 2015 Aug;47(8):906-10. doi: 10.1038/ng.3342. Epub 2015 Jun 22.
95 Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):281-7. doi: 10.1158/1055-9965.EPI-05-0539.
96 PLCE1 mRNA and protein expression and survival of patients with esophageal squamous cell carcinoma and gastric adenocarcinoma.Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1579-1588. doi: 10.1158/1055-9965.EPI-13-1329. Epub 2014 May 27.
97 GlcNAc and its catalyst 4GnT are diagnostic and prognostic markers in uterine cervical tumor, gastric type.Sci Rep. 2019 Sep 10;9(1):13043. doi: 10.1038/s41598-019-49376-7.
98 Annexin A7 expression is downregulated in late-stage gastric cancer and is negatively correlated with the differentiation grade and apoptosis rate.Oncol Lett. 2018 Jun;15(6):9836-9844. doi: 10.3892/ol.2018.8576. Epub 2018 Apr 25.
99 Whole-exome sequencing capture kit biases yield false negative mutation calls in TCGA cohorts.PLoS One. 2018 Oct 3;13(10):e0204912. doi: 10.1371/journal.pone.0204912. eCollection 2018.
100 CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.J Pathol. 2005 Apr;205(5):615-22. doi: 10.1002/path.1741.
101 Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2.Oncol Lett. 2018 May;15(5):7617-7624. doi: 10.3892/ol.2018.8342. Epub 2018 Mar 23.
102 Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements.Nat Commun. 2014 Jul 10;5:4361. doi: 10.1038/ncomms5361.
103 Methylation of the claudin? promoter predicts the prognosis of advanced gastric adenocarcinoma.Oncol Rep. 2018 Jul;40(1):49-60. doi: 10.3892/or.2018.6411. Epub 2018 May 2.
104 Chondromodulin-1 functions as a tumor suppressor in gastric adenocarcinoma.Int J Oncol. 2015 Sep;47(3):941-50. doi: 10.3892/ijo.2015.3081. Epub 2015 Jul 13.
105 Key Genes in Stomach Adenocarcinoma Identified via Network Analysis of RNA-Seq Data.Pathol Oncol Res. 2017 Oct;23(4):745-752. doi: 10.1007/s12253-016-0178-y. Epub 2017 Jan 5.
106 Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.Tumour Biol. 2015 Nov;36(11):8247-57. doi: 10.1007/s13277-015-3972-3. Epub 2015 Sep 14.
107 CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma.J Cell Physiol. 2019 Mar;234(3):2895-2904. doi: 10.1002/jcp.27106. Epub 2018 Aug 4.
108 Epigenetic alterations of CYLD promoter modulate its expression in gastric adenocarcinoma: A footprint of infections.J Cell Physiol. 2019 Apr;234(4):4115-4124. doi: 10.1002/jcp.27220. Epub 2018 Aug 21.
109 MicroRNA-214 promotes the proliferation, migration and invasion of gastric cancer MKN28 cells by suppressing the expression of Dact2.Exp Ther Med. 2018 Dec;16(6):4909-4917. doi: 10.3892/etm.2018.6771. Epub 2018 Sep 19.
110 DOK2 as a marker of poor prognosis of patients with gastric adenocarcinoma after curative resection.Ann Surg Oncol. 2012 May;19(5):1560-7. doi: 10.1245/s10434-011-2157-6. Epub 2011 Dec 1.
111 Increased RCAS1 expression is associated with advanced histopathological stage and poor prognosis in patients with gastric adenocarcinoma.Dis Markers. 2013;35(4):213-9. doi: 10.1155/2013/527548. Epub 2013 Sep 3.
112 ER membrane protein complex subunit 6 (EMC6) is a novel tumor suppressor in gastric cancer.BMB Rep. 2017 Aug;50(8):411-416. doi: 10.5483/bmbrep.2017.50.8.065.
113 EPSIN 3, A Novel p53 Target, Regulates the Apoptotic Pathway and Gastric Carcinogenesis.Neoplasia. 2017 Mar;19(3):185-195. doi: 10.1016/j.neo.2016.12.010. Epub 2017 Jan 30.
114 Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma.BMC Gastroenterol. 2018 Jun 8;18(1):81. doi: 10.1186/s12876-018-0811-1.
115 FAT4 hypermethylation and grade dependent downregulation in gastric adenocarcinoma.J Cell Commun Signal. 2017 Mar;11(1):69-75. doi: 10.1007/s12079-016-0355-5. Epub 2016 Oct 1.
116 Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.Int J Med Sci. 2006 Nov 1;4(1):1-6. doi: 10.7150/ijms.4.1.
117 GalNAc-T15 in gastric adenocarcinoma: Characterization according to tissue architecture and cellular location.Eur J Histochem. 2018 Jun 14;62(2):2931. doi: 10.4081/ejh.2018.2931.
118 The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.Am J Cancer Res. 2018 Sep 1;8(9):1739-1751. eCollection 2018.
119 The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics.Front Cell Infect Microbiol. 2018 Dec 12;8:433. doi: 10.3389/fcimb.2018.00433. eCollection 2018.
120 An Integrated Pan-Cancer Analysis and Structure-Based Virtual Screening of GPR15.Int J Mol Sci. 2019 Dec 10;20(24):6226. doi: 10.3390/ijms20246226.
121 Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas.Jpn J Cancer Res. 1995 Apr;86(4):333-5. doi: 10.1111/j.1349-7006.1995.tb03060.x.
122 Nuclear overexpression of the overexpressed in lung cancer 1 predicts worse prognosis in gastric adenocarcinoma.Oncotarget. 2017 Feb 7;8(6):9442-9450. doi: 10.18632/oncotarget.14217.
123 CDX1/2 and KLF5 Expression and Epigenetic Modulation of Sonic Hedgehog Signaling in Gastric Adenocarcinoma.Pathol Oncol Res. 2019 Jul;25(3):1215-1222. doi: 10.1007/s12253-019-00594-4. Epub 2019 Jan 26.
124 Overexpression of KPNA2 correlates with poor prognosis in patients with gastric adenocarcinoma.Tumour Biol. 2013 Apr;34(2):1021-6. doi: 10.1007/s13277-012-0641-7. Epub 2013 Jan 3.
125 LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.Front Immunol. 2019 Jan 29;10:6. doi: 10.3389/fimmu.2019.00006. eCollection 2019.
126 LETM1 is a potential biomarker that predicts poor prognosis in gastric adenocarcinoma.Exp Mol Pathol. 2020 Feb;112:104333. doi: 10.1016/j.yexmp.2019.104333. Epub 2019 Nov 6.
127 PINCH expression and its clinicopathological significance in gastric adenocarcinoma.Dis Markers. 2012;33(4):171-8. doi: 10.3233/DMA-2012-0930.
128 Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma.Gastric Cancer. 2016 Apr;19(2):453-465. doi: 10.1007/s10120-015-0514-z. Epub 2015 Jul 24.
129 Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance.Med Sci Monit. 2018 Jan 18;24:348-355. doi: 10.12659/msm.908447.
130 High adherence to the Western, Prudent, and Mediterranean dietary patterns and risk of gastric adenocarcinoma: MCC-Spain study.Gastric Cancer. 2018 May;21(3):372-382. doi: 10.1007/s10120-017-0774-x. Epub 2017 Nov 14.
131 Clinical and prognostic implications of 1, 6-N-acetylglucosaminyltransferase V in patients with gastric cancer.Cancer Sci. 2013 Feb;104(2):185-93. doi: 10.1111/cas.12049. Epub 2012 Dec 6.
132 Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.Cancer Sci. 2014 Jan;105(1):126-33. doi: 10.1111/cas.12305. Epub 2013 Nov 22.
133 Prognostic significance of neuroepithelial transforming gene 1 in adenocarcinoma of the oesophagogastric junction.Br J Surg. 2014 Jan;101(2):55-62. doi: 10.1002/bjs.9373.
134 Polystyrene nanoparticles internalization in human gastric adenocarcinoma cells.Toxicol In Vitro. 2016 Mar;31:126-36. doi: 10.1016/j.tiv.2015.11.006. Epub 2015 Nov 14.
135 Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma.Anticancer Res. 2017 Aug;37(8):4475-4481. doi: 10.21873/anticanres.11843.
136 Reversal of multidrug resistance of vincristine-resistant gastric adenocarcinoma cells through up-regulation of DARPP-32. Cell Biol Int. 2007 Sep;31(9):1010-5. doi: 10.1016/j.cellbi.2007.03.020. Epub 2007 Mar 21.
137 High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.Med Sci Monit. 2018 Oct 23;24:7556-7562. doi: 10.12659/MSM.911531.
138 PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.Anticancer Res. 2006 Mar-Apr;26(2B):1643-9.
139 Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.PLoS One. 2014 Nov 20;9(11):e113754. doi: 10.1371/journal.pone.0113754. eCollection 2014.
140 PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.Onco Targets Ther. 2018 Nov 2;11:7795-7803. doi: 10.2147/OTT.S178152. eCollection 2018.
141 Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer.Oncol Lett. 2018 Apr;15(4):5185-5192. doi: 10.3892/ol.2018.7992. Epub 2018 Feb 7.
142 Long noncoding RNA RP1?63G9.1 is downregulated in gastric adenocarcinoma and is associated with a poor prognosis.Oncol Rep. 2019 Jun;41(6):3575-3585. doi: 10.3892/or.2019.7127. Epub 2019 Apr 17.
143 Mina53, a novel molecular marker for the diagnosis and prognosis of gastric adenocarcinoma.Oncol Rep. 2014 Feb;31(2):634-40. doi: 10.3892/or.2013.2918. Epub 2013 Dec 12.
144 Overexpression of rho effector rhotekin confers increased survival in gastric adenocarcinoma.J Biomed Sci. 2004 Sep-Oct;11(5):661-70. doi: 10.1007/BF02256132.
145 Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.Clin Cancer Res. 2018 Nov 15;24(22):5724-5734. doi: 10.1158/1078-0432.CCR-17-3364. Epub 2018 May 29.
146 Human SBK1 is dysregulated in multiple cancers and promotes survival of ovary cancer SK-OV-3 cells.Mol Biol Rep. 2011 Jun;38(5):3551-9. doi: 10.1007/s11033-010-0465-8. Epub 2010 Nov 20.
147 Frequent loss of heterozygosity of SMAD4 locus and prognostic impacts of SMAD4 immunohistochemistry in gastric adenocarcinoma with enteroblastic differentiation.Hum Pathol. 2019 Jun;88:18-26. doi: 10.1016/j.humpath.2019.03.005. Epub 2019 Apr 1.
148 Prognostic value of sorting nexin 10 weak expression in stomach adenocarcinoma revealed by weighted gene co-expression network analysis.World J Gastroenterol. 2018 Nov 21;24(43):4906-4919. doi: 10.3748/wjg.v24.i43.4906.
149 Sorcin a Potential Molecular Target for Cancer Therapy.Transl Oncol. 2018 Dec;11(6):1379-1389. doi: 10.1016/j.tranon.2018.08.015. Epub 2018 Sep 11.
150 Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer.BMC Cancer. 2016 Jun 10;16:358. doi: 10.1186/s12885-016-2387-x.
151 Evaluation of the expression and clinical value of lncRNA AC010761.9 in human gastric adenocarcinoma.World J Surg Oncol. 2018 Mar 2;16(1):40. doi: 10.1186/s12957-017-1289-y.
152 TRIM15 Exerts Anti-Tumor Effects Through Suppressing Cancer Cell Invasion in Gastric Adenocarcinoma.Med Sci Monit. 2018 Nov 9;24:8033-8041. doi: 10.12659/MSM.911142.
153 TRIM25 blockade by RNA interference inhibited migration and invasion of gastric cancer cells through TGF- signaling.Sci Rep. 2016 Jan 12;6:19070. doi: 10.1038/srep19070.
154 High expression of ALPPL2 is associated with poor prognosis in gastric cancer.Hum Pathol. 2019 Apr;86:49-56. doi: 10.1016/j.humpath.2018.11.019. Epub 2018 Nov 26.
155 ANKRD33 is overexpressed in gastric adenocarcinoma and predictive for poor prognosis.Biosci Biotechnol Biochem. 2019 Nov;83(11):2075-2081. doi: 10.1080/09168451.2019.1642100. Epub 2019 Jul 17.
156 Comprehensive analysis of histone modification-associated genes on differential gene expression and prognosis in gastric cancer.Exp Ther Med. 2019 Sep;18(3):2219-2230. doi: 10.3892/etm.2019.7808. Epub 2019 Jul 24.
157 Pathogenic Germline Variants in 10,389 Adult Cancers.Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039.
158 Both gene deletion and promoter hyper-methylation contribute to the down-regulation of ZAC/PLAGL1 gene in gastric adenocarcinomas: a case control study.Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):744-50. doi: 10.1016/j.clinre.2013.06.007. Epub 2014 Aug 1.